6.
Kannel W, Hjortland M, CASTELLI W
. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34(1):29-34.
DOI: 10.1016/0002-9149(74)90089-7.
View
7.
Holman R, Sourij H, Califf R
. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014; 383(9933):2008-17.
DOI: 10.1016/S0140-6736(14)60794-7.
View
8.
Ferraro E, Giammarioli A, Caldarola S, Lista P, Feraco A, Tinari A
. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J. 2013; 280(20):5094-108.
DOI: 10.1111/febs.12484.
View
9.
Stolen T, Hoydal M, Kemi O, Catalucci D, Ceci M, Aasum E
. Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res. 2009; 105(6):527-36.
DOI: 10.1161/CIRCRESAHA.109.199810.
View
10.
Sacre J, Franjic B, Jellis C, Jenkins C, Coombes J, Marwick T
. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010; 3(12):1207-15.
DOI: 10.1016/j.jcmg.2010.09.014.
View
11.
Penpargkul S, Fein F, SONNENBLICK E, Scheuer J
. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981; 13(3):303-9.
DOI: 10.1016/0022-2828(81)90318-7.
View
12.
Samuel V
. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab. 2010; 22(2):60-5.
DOI: 10.1016/j.tem.2010.10.003.
View
13.
Zhou Y, Marlen K, Palma J, Schweitzer A, Reilly L, Gregoire F
. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity?. J Biol Chem. 2003; 278(51):51316-23.
DOI: 10.1074/jbc.M307972200.
View
14.
Baudrand R, Gupta N, Garza A, Vaidya A, Leopold J, Hopkins P
. Caveolin 1 Modulates Aldosterone-Mediated Pathways of Glucose and Lipid Homeostasis. J Am Heart Assoc. 2016; 5(10).
PMC: 5121487.
DOI: 10.1161/JAHA.116.003845.
View
15.
Juurlink D, Gomes T, Lipscombe L, Austin P, Hux J, Mamdani M
. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009; 339:b2942.
PMC: 2728804.
DOI: 10.1136/bmj.b2942.
View
16.
Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A
. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357.
DOI: 10.1056/NEJMoa1812389.
View
17.
Anderson E, Kypson A, Rodriguez E, Anderson C, Lehr E, Neufer P
. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009; 54(20):1891-8.
PMC: 2800130.
DOI: 10.1016/j.jacc.2009.07.031.
View
18.
Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco R, Homma S
. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol. 2008; 101(12):1787-91.
PMC: 2486269.
DOI: 10.1016/j.amjcard.2008.02.082.
View
19.
Shome J, Perera D, Plein S, Chiribiri A
. Current perspectives in coronary microvascular dysfunction. Microcirculation. 2016; 24(1).
DOI: 10.1111/micc.12340.
View
20.
Uchimura K, Hayata M, Mizumoto T, Miyasato Y, Kakizoe Y, Morinaga J
. The serine protease prostasin regulates hepatic insulin sensitivity by modulating TLR4 signalling. Nat Commun. 2014; 5:3428.
PMC: 3959208.
DOI: 10.1038/ncomms4428.
View